cure drpla
  • Home
  • ABOUT
    • About DRPLA
    • Who We Are
  • CURRENT INITIATIVES
    • Global Patient Registry
    • Patient & Caregiver
    • Researchers & Industry
    • DRPLA Centers of Excellence
  • News and Announcements
    • Announcements
    • News Articles
    • Events
  • Français
  • Italiano
  • Português
  • 日本語
  • 한국어

Prof Darren Monckton joins CureDRPLA as Scientific Consultant

by Silvia Prades | Jul 30, 2025 | Announcements

Darren Monckton is a Professor of Human Genetics at the University of Glasgow and he will be advising CureDRPLA on scientific matters. Prof Monckton brings years of experience in research for conditions like Huntington’s disease and Myotonic Dystrophy. His expertise...
Recruitment update for the DRPLA Natural History and Biomarkers Study

Recruitment update for the DRPLA Natural History and Biomarkers Study

by Silvia Prades | Jul 30, 2025 | News Articles

CureDRPLA is funding this study to better understand the symptoms of DRPLA and how they change over time. It also aims to identify measurable indicators that could predict progression and responsiveness to treatments in future clinical trials. This study collects...
Strengthening ties with Japan’s rare disease community

Strengthening ties with Japan’s rare disease community

by Silvia Prades | Jul 30, 2025 | News Articles

Since DRPLA is more prevalent in Japan, CureDRPLA has made it a priority to build connections with the scientific and clinical community there. Junko Shiozawa, Advisory Board Member, has played a key role in building a community of Japanese individuals affected by...
Characterizing DRPLA mouse model and testing potential therapeutics – an update from Dr Jeff Carroll’s group

Characterizing DRPLA mouse model and testing potential therapeutics – an update from Dr Jeff Carroll’s group

by Silvia Prades | Apr 16, 2025 | News Articles

In this video we interviewed Aliza Ben-Varon, a former Graduate Student working with Dr Jeff Carroll at the University of Washington. This research group has done a fantastic job in characterizing a mouse model that mimics the human form of DRPLA. Using genetic...
Nissan Chemical and Sanwa Kagaku formalize agreement to collaboratively develop a drug for DRPLA

Nissan Chemical and Sanwa Kagaku formalize agreement to collaboratively develop a drug for DRPLA

by Silvia Prades | Apr 9, 2025 | News Articles

Nissan Chemical Corporation and Sanwa Kagaku Kenkyusho Co., Ltd., two Japanese companies, announced on April 4 their agreement to co-develop SK-2407/SN-001, which is a pre-clinical antisense oligonucleotide (ASO) candidate identified through their collaboration for...
« Older Entries

Recent Posts

  • Prof Darren Monckton joins CureDRPLA as Scientific Consultant
  • Recruitment update for the DRPLA Natural History and Biomarkers Study
  • Strengthening ties with Japan’s rare disease community
  • Characterizing DRPLA mouse model and testing potential therapeutics – an update from Dr Jeff Carroll’s group
  • Nissan Chemical and Sanwa Kagaku formalize agreement to collaboratively develop a drug for DRPLA

Recent Comments

    Andrea Compton

    President & Co-Founder

    Paul Compton

    Co-Founder

    info@cureDRPLA.org

    cureDRPLA.org

    @cureDRPLA

    Andrea Compton

    Register at Rare Connect

    cure drpla

    Contact Us


    info@cureDRPLA.org

    Helping Families and Individuals Worldwide

    Thank you for visiting our site. Please be in touch with us personally to share your story or any relevant information. Together, we may be able to develop a better understanding and potential treatments or a cure for DRPLA.

    • Home
    • About DRPLA
    • Who We Are
    • Global Patient Registry
    • Patient & Caregiver
    • Researchers & Industry
    • DRPLA Centers of Excellence
    • Events
    • English
      • English
      • Français
      • Italiano
      • Português
      • 日本語
      • 한국어

    Copyright © 2021 CureDRPLA. All rights reserved.